Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics have reported positive topline data from Hengrui’s Phase II obesity trial, considering an 8mg dose of the companies’ GLP-1/GIP receptor ...

Additionally, a 2023 study suggested that during the weight-loss phase of treatment ... patients taking a GLP-1 RA or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, but few ...

REUTERS Eli Lilly’s drug is called “triple G” because it mimics GLP-1, the appetite-suppressing hormone GIP and glucagon, a hormone that helps control blood sugar levels. Phase 3 trials are ...

--(BUSINESS WIRE)--Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretion of GLP-1 and ...

Viking Therapeutics is expected to lead this group with its dual GLP-1RA/gastric inhibitory polypeptide receptor (GIP-R) agonist, VK-2735, which is in Phase II for obesity with an oral route of ...

Kailera unveiled the Zepbound-matching phase 2 data for KAI-9531 at the start of this year. As Fierce Biotech noted at the time, Zepbound—also a dual GIP and GLP-1 receptor agonist—showed ...

gastric inhibitory polypeptide (GIP), in addition to GLP-1. This drug has shown a maximum weight loss of 20 percent at the highest dose strength after 72 weeks. CagriSema combines semaglutide with ...

today announced positive data from a 12-week Phase 2a clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA).

Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretion of GLP-1 and GIP, in US patent US 12,171,727 B1 ...